Nimotop S (Nimodipine)

Nimodipine, the active ingredient in Nimotop S, is a calcium channel blocker presented as an oral tablet for oral use. It prevents and treats cerebral vasospasm following subarachnoid hemorrhage. GNH USA supplies Nimotop S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimodipine is used to address vascular complications within the central nervous system, particularly after subarachnoid hemorrhage. - Cerebral vasospasm after subarachnoid hemorrhage: reduces vasoconstriction and improves cerebral blood flow. - Neuroprotection after subarachnoid hemorrhage: helps limit secondary neuronal injury and ischemic deficits.

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drops in blood pressure. - Nausea: occasional gastrointestinal upset. - Flushing: warmth and redness of skin. - Dizziness: especially when standing quickly. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Myocardial infarction: rare cardiac events. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or angioedema. - Stevens‑Johnson syndrome: severe skin reaction. - Blood dyscrasias: thrombocytopenia or leukopenia.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal impairment: assess renal function and monitor for accumulation. - Hepatic impairment: use with caution and observe liver enzymes. - Hypotension: monitor blood pressure regularly, especially after dose initiation. - Concomitant vasodilators: increased risk of additive blood‑pressure lowering effects. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nimodipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower effectiveness. - Other calcium‑channel blockers: additive vasodilatory effect leading to profound hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: enhanced hypotensive response. - Nitrates: increased risk of low blood pressure. - Diuretics: may potentiate orthostatic hypotension.